Current Vascular Pharmacology
Title:Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)
Volume: 14 Issue: 5
Author(s): Vasilios G. Athyros, Niki Katsiki and Nikolaos Tentolouris
Affiliation:
Keywords: Glucagon-like-peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, type 2 diabetes mellitus, cardiovascular disease, heart failure.
Export Options
About this article
Cite this article as:
Athyros G. Vasilios, Katsiki Niki and Tentolouris Nikolaos, Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial), Current Vascular Pharmacology 2016; 14 (5) . https://dx.doi.org/10.2174/1570161114666160909161537
DOI https://dx.doi.org/10.2174/1570161114666160909161537 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological Mechanisms of Action of Incretin and Insulin in Regulating Skeletal Muscle Metabolism
Current Diabetes Reviews Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Stress and Aging
Current Genomics Interatrial Block in the Modern Era
Current Cardiology Reviews Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Control of the Bone Morphogenetic Protein 7 Gene in Developmental and Adult Life
Current Genomics Multiple Lipid-lowering Treatment in Pediatric Patients with Hyperlipidemia
Medicinal Chemistry High-Density Lipoprotein: Key Molecule in Cholesterol Efflux and the Prevention of Atherosclerosis
Current Pharmaceutical Design Relaxin, Insulin and Diabetes: An Intriguing Connection
Current Diabetes Reviews Novel Functions of MicroRNA-17-92 Cluster in the Endocrine System
Current Drug Targets GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
Current Pharmaceutical Design Nicotinamide as a Foundation for Treating Neurodegenerative Disease and Metabolic Disorders
Current Neurovascular Research Editorial [Hot Topic: Promote Healthy Eating in Women of Childbearing Age (Guest Editor: Hiroko Watanabe)]
Current Nutrition & Food Science Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases
Current Pharmaceutical Design Advances in Structural Modifications and Biological Activities of Berberine: An Active Compound in Traditional Chinese Medicine
Mini-Reviews in Medicinal Chemistry Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets